BioMarin halts Voxzogo trials due to safety signal BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

#BioMarin has suspended dosing in phase 2 trials of its #achondroplasia therapy #Voxzogo aimed at broadening its label, while it investigates a potential #safety issue.

BioMarin's VOXZOGO Shows Positive Growth Outcomes for Children with Achondroplasia BioMarin Pharmaceuticals shares new data on the effectiveness of VOXZOGO in promoting growth in children with achondroplasia, demonstrating significant early treatment benefits.

BioMarin's VOXZOGO Shows Positive Growth Outcomes for Children with Achondroplasia #United_States #San_Rafael #BioMarin #VOXZOGO #achondroplasia

Maternal decision-making through temporal uncertainties: The anticipatory biopolitics of Vosoritide in dwarfism communities - PubMed Vosoritide, a biotechnological therapy designed to increase growth in children with achondroplasia, has introduced new pressures and bodily possibilities for families navigating this rare genetic condition. While debates around its use often centre on its efficacy as a non-surgical growth treatment …

pubmed.ncbi.nlm.nih.gov/41762856/

#Dwarfism #Voxzogo #Achondroplasia #Vosoritide

BioMarin Pharmaceutical Inc. Reports Significant Growth in Revenues and Plans for 2026 Acquisitions BioMarin Pharmaceutical Inc. showcased an impressive revenue growth for 2025 and announced future acquisition plans that could elevate its market position significantly.

BioMarin Pharmaceutical Inc. Reports Significant Growth in Revenues and Plans for 2026 Acquisitions #USA #San_Rafael #BioMarin #VOXZOGO #Amicus_Therapeutics

BioMarin Pharmaceutical Announces Third Quarter 2025 Financial Results and Strategic Developments In its latest financial report, BioMarin Pharmaceutical showcases impressive growth and strategic portfolio realignment, highlighting key therapies and future initiatives.

BioMarin Pharmaceutical Announces Third Quarter 2025 Financial Results and Strategic Developments #United_States #San_Rafael #BioMarin_Pharmaceutical #VOXZOGO #PALYNZIQ

Future of the Global Voxzogo Market: Growth Projections and Key Trends (2025-2034) - Good PR News How big is the voxzogo market today, and what are its future growth expectations? The voxzogo market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 a...

🧬 Voxzogo Global Market Report 2025 | Emerging Trends, Demand & Forecast Insights

Read More @ goodprnews.com/future-of-th...

#marketresearchreport #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #Voxzogo

BioMarin Presents Groundbreaking Data on Bone Health Improvement at ASBMR 2025 At ASBMR 2025, BioMarin highlights key findings from 14 studies showcasing VOXZOGO's impact on spinal morphology and growth in children with achondroplasia.

BioMarin Presents Groundbreaking Data on Bone Health Improvement at ASBMR 2025 #USA #Seattle,_Washington #BioMarin #Bone_Health #VOXZOGO

BioMarin Highlights Impressive Second Quarter 2025 Earnings and Plans Ahead for Growth BioMarin Pharmaceutical Inc. reports significant revenue growth in Q2 2025, raising full-year guidance. New therapies and acquisitions contribute to strong pipeline progress.

BioMarin Highlights Impressive Second Quarter 2025 Earnings and Plans Ahead for Growth #USA #San_Rafael #BioMarin #VOXZOGO #BMN_333

BioMarin Showcases Promising VOXZOGO Data at Key Endocrinology Meetings BioMarin Pharmaceutical has announced encouraging findings for VOXZOGO, showcasing its benefits in children with achondroplasia and other skeletal conditions at international endocrinology events.

BioMarin Showcases Promising VOXZOGO Data at Key Endocrinology Meetings #USA #San_Rafael #BioMarin #VOXZOGO #achondroplasia

BioMarin Pharmaceuticals Delivers Strong Q1 Results and Maintains Full-Year Projections for 2025 BioMarin Pharmaceutical Inc. reported substantial financial gains in Q1 2025, reaffirming its full-year guidance with a strong outlook for growth and innovative therapy launches.

BioMarin Pharmaceuticals Delivers Strong Q1 Results and Maintains Full-Year Projections for 2025 #United_States #San_Rafael #BioMarin #VOXZOGO #PALYNZIQ

Cartoonjournaal 26 april 2025

Lees het bijbehorende bericht op mijn LinkedIn profiel:

www.linkedin.com/posts/lokoca...

#cartoonjournaal #nieuws #actualiteit #humor #cartoon

#petitie #achondroplasie #dwerggroei #Voxzogo #medicijn #gezondheidszorg #zorg

BioMarin Unveils Promising Data on VOXZOGO for Young Children with Achondroplasia at ACMG 2025 At the 2025 ACMG Annual Clinical Genetics Meeting, BioMarin revealed promising data for VOXZOGO in children with achondroplasia, emphasizing safety and adherence.

BioMarin Unveils Promising Data on VOXZOGO for Young Children with Achondroplasia at ACMG 2025 #United_States #Los_Angeles #BioMarin #VOXZOGO #achondroplasia

BioMarin Pharmaceuticals: A Record-Breaking Year with Promising Growth Ahead BioMarin Pharmaceutical Inc. announces impressive results for 2024 and sets optimistic guidance for 2025, emphasizing strong growth and innovation.

BioMarin Pharmaceuticals: A Record-Breaking Year with Promising Growth Ahead #United_States #financial_results #San_Rafael #BioMarin_Pharmaceutical #VOXZOGO